To assess diffuse liver disease, MRI is currently the modality of choice. New developments in artificial intelligence (AI) could tip the scales in favour of CT imaging. At ECR 2022 in July, experts showed how AI technology enables CT to quantify liver fat as exquisitely as MRI.
Even as we battle one pandemic (Covid-19), we sit on the cusp of another. Europe has one of the highest burdens of chronic liver disease (CLD) in the world, driven largely by alcohol overconsumption, viral hepatitis, and obesity. Furthermore, non-alcoholic fatty liver disease (NAFLD) is increasingly common and is a significant contributor to CLD – especially in people with diabetes, where its…
Professor Dina Tiniakos, from the National and Kapodistrian University of Athens, predicts that NASH (Non-alcohol related steatohepatitis) cases will soar worldwide by 2030, with 800,000 liver deaths, costing health economies billions of dollars.
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in western countries, with an increasing incidence worldwide. Consequences of NAFLD can also include kidney disease and kidney stones, although the mechanisms for the development of these kidney complications as a result of NAFLD have not yet been fully explained. Researchers at the Leibniz Research Centre for Working…
With the application of a novel 3D imaging technology, researchers at Karolinska Institutet have discovered that one portion of the autonomic nervous system in the liver undergoes severe degeneration in non-alcoholic fatty liver disease. The study, which is conducted in mice and human liver tissue, shows that the degeneration of nerves is correlated with the severity of liver pathology. The…
Rather than using techniques separately, researchers have determined that coupling image-based and serum-based biomarkers achieves a higher diagnostic accuracy in detecting stage two liver fibrosis, or above. The study team, from the NAFLD Research Center, University of California at San Diego (UCSD), and colleagues at Yokohama City University in Japan, used magnetic resonance elastography (MRE)…
It’s currently difficult to screen for certain liver diseases and to monitor these conditions once they’re discovered. A team led by investigators at Massachusetts General Hospital (MGH) and the Massachusetts Institute of Technology (MIT) recently developed a non-invasive imaging method that has promising clinical potential to accomplish both goals. The technique is described in a study…
Non-alcoholic fatty liver disease (NAFLD) is mostly diagnosed in overweight and obese people. However, severe forms of NAFLD can also be detected in rare genetic diseases such as lipodystrophy or in patients with HIV, putting them at a high risk for developing liver failure, diabetes and cardiovascular diseases. Norbert Stefan and colleagues have now detected a yet unknown cause of NAFLD in lean…
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disorder in developed countries. Histological analysis of liver tissue is the only widely accepted test for diagnosing and distinguishing different stages of NAFLD. However, this technique provides only two-dimensional images of the liver tissue in low resolution and overlooks potentially important 3D structural…
A pioneering European research project designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to more patients. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint undertaking, brings together clinical scientists from international…
The traditional classification of diabetes, mainly in type 1 and type 2 diabetes, has been challenged by studies from Scandinavia. In the current issue of The Lancet Diabetes & Endocrinology, researchers from DDZ together with colleagues from DZD and University of Lund published a cluster analysis of diabetes allowing for phenotyping into subgroups, which extended the findings by showing that…
Non-alcoholic fatty liver disease (NAFLD) is a condition where fat accumulates in the liver and has become the most common liver disease worldwide. While NAFLD shows few or no symptoms at initial stages, it is a potentially serious disease which can progress to an inflammatory state called steatohepatitis (NASH), which can lead to liver cirrhosis and cancer. Fatty liver disease can be managed by…
Approximately 10 percent of the general population take a proton pump inhibitor (PPI) drug to block stomach acid secretions and relieve symptoms of frequent heartburn, acid reflux and gastroesophageal reflux disease. That percentage can be as much as seven times higher for people with chronic liver disease. Researchers at University of California San Diego School of Medicine have discovered…
German researches have linked the increased production of a certain enzyme in the liver to fatty liver and insulin resistance.
Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent liver diseases worldwide and an estimated 20 million people in Germany are affected.